{
  "patent_number": "US 20210205465",
  "country": "US",
  "title": "Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease",
  "original_title": "Aberrant cell-restricted immunoglobulins provided with a toxic moiety",
  "summary": "This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them.",
  "what_it_does": "This patent describes a specialized antibody, called an immunoglobulin, that carries a toxic substance, or 'toxic moiety' (Claim 1). This antibody is designed to specifically attach to a unique flag, an 'MHC-peptide complex,' that is found mostly on 'aberrant cells' – which are diseased cells like cancer or those involved in autoimmune conditions (Claim 1). The toxic substance can be chemically attached to the antibody or even built into it at the genetic level as a 'fusion protein' (Claims 6, 7). The goal is to deliver this toxic payload directly to the aberrant cells, potentially even getting the toxin inside them (Claim 10), to treat diseases like cancer (Claim 11). For example, an antibody could be engineered to find a specific MHC-peptide complex on a melanoma cell, then deliver a cell-killing drug directly to that cell.",
  "what_it_does_not_cover": [
    "Does not cover immunoglobulins that do not have a toxic moiety attached to them.",
    "Does not cover toxic therapies where the toxic agent is not specifically delivered by an immunoglobulin.",
    "Does not cover immunoglobulins that target cells by binding to something other than an MHC-peptide complex.",
    "Does not cover immunoglobulins that bind to MHC-peptide complexes that are equally common on both healthy and diseased cells.",
    "Does not cover immunoglobulins that target aberrant cells but are not specifically designed to bind to an MHC-peptide complex."
  ],
  "filed": "2021-01-11",
  "granted": null,
  "expires": "2041-01-11",
  "status": "active",
  "holder": "Apo T BV",
  "holder_url": "https://patentbrief.org/company/apo-t-bv",
  "inventors": [
    {
      "name": "Ralph Alexander Willemsen",
      "url": "https://patentbrief.org/inventor/ralph-alexander-willemsen"
    },
    {
      "name": "Johan Renes",
      "url": "https://patentbrief.org/inventor/johan-renes"
    },
    {
      "name": "Paulus J.G.M. Steverink",
      "url": "https://patentbrief.org/inventor/paulus-jgm-steverink"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "gene_editing"
  ],
  "abstract": "Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety may be used in selectively modulating biological processes. These immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrations, such as cancers and autoimmune diseases.",
  "url": "https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety",
  "markdown_url": "https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety/md",
  "google_patents_url": "https://patents.google.com/patent/US20210205465",
  "relatedPatents": []
}